Investment
Features
FeesSafety
Academy
More
Pluang+

Relay Therapeutics advances zovegalisib + atirmociclib combo to Phase 3 for frontline metastatic breast cancer

Company Fundamentals
27 Apr 2026
Relay Therapeutics
View Source
Bullish
pluang ai news

Relay Therapeutics announced plans to start a Phase 3 trial in early 2027 for a new triplet drug regimen combining zovegalisib, atirmociclib, and an aromatase inhibitor to treat frontline metastatic breast cancer with PIK3CA mutations. Early clinical data showed a 44% response rate in heavily pre-treated patients, with good tolerability and manageable side effects. The combination aims to improve treatment options with an all-oral regimen and has a supply agreement with Pfizer for atirmociclib. The Phase 3 trial will compare this triplet against current standard treatments, focusing on progression-free survival and overall survival.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App